Dual block versus single agent trastuzumab plus chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials

被引：0
|
作者：
Clavarezza, M. [1 ]
Puntoni, M. [2 ]
Gennari, A. [1 ]
Paleari, L. [1 ]
Provinciali, N. [1 ]
D'Amico, M. [1 ]
Decensi, A. [1 ]
机构：
[1] Osped Galliera, Oncol Unit, Genoa, Italy
[2] Osped Galliera, Clin Trial & Biostat Unit, Sci Direct, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw364.60
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
204P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials
    Clavarezza, Matteo
    Puntoni, Matteo
    Gennari, Alessandra
    Paleari, Laura
    Provinciali, Nicoletta
    D'Amico, Mauro
    DeCensi, Andrea
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4594 - 4603
  • [2] The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
    Chen, Zhe-Ling
    Shen, Yan-Wei
    Li, Shu-Ting
    Li, Chun-Li
    Zhang, Ling-Xiao
    Yang, Jiao
    Lv, Meng
    Lin, Ya-Yun
    Wang, Xin
    Yang, Jin
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 3233 - 3247
  • [3] Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Yu, Liuwen
    Fu, Fangmeng
    Li, Jing
    Huang, Meng
    Zeng, Bangwei
    Lin, Yuxiang
    Mei, Qian
    Lv, Jinxing
    Wang, Chuan
    [J]. JOURNAL OF ONCOLOGY, 2020, 2020
  • [4] Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
    Guarneri, V
    Griguolo, G.
    Miglietta, F.
    Conte, P. F.
    Dieci, M., V
    Girardi, F.
    [J]. ESMO OPEN, 2022, 7 (02)
  • [5] Tumor infiltrating lymphocytes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of published randomized clinical trials
    Solinas, C.
    Ceppi, M.
    Lambertini, M.
    Scartozzi, M.
    Garaud, S.
    Fumagalli, D.
    De Azambuja, E.
    Salgado, R.
    Willard-Gallo, K.
    Ignatiadis, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [6] Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials
    Solinas, C.
    Ceppi, M.
    Lambertini, M.
    Scartozzi, M.
    Buisseret, L.
    Garaud, S.
    Fumagalli, D.
    de Azambuja, E.
    Salgado, R.
    Sotiriou, C.
    Willard-Gallo, K.
    Ignatiadis, M.
    [J]. CANCER TREATMENT REVIEWS, 2017, 57 : 8 - 15
  • [7] Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis
    Valachis, Antonis
    Mauri, Davide
    Polyzos, Nikolaos P.
    Chlouverakis, Grigoris
    Mavroudis, Dimitrios
    Georgoulias, Vassilios
    [J]. BREAST, 2011, 20 (06): : 485 - 490
  • [8] ADJUVANT TRASTUZUMAB THERAPY IN HER2-POSITIVE BREAST CANCER PATIENTS: A META-ANALYSIS OF PUBLISHED RANDOMIZED TRIALS
    Xia, Y.
    Bian, B.
    Costea, E.
    Kelton, C. M.
    Guo, J. J.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A128 - A128
  • [9] Adjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer Patients: A Meta-Analysis of Published Randomized Trials
    Xia, Ying
    Bian, Boyang
    Costea, Elizabeth
    Guo, Jeff
    Kelton, Christina
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 131 - 132
  • [10] A Meta-Analysis of Randomized Controlled Trials Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Alone in HER-2-Positive Advanced Breast Cancer
    Liao, Cun
    Yin, Fang
    Huang, Ping
    Cao, Yunfei
    Gao, Feng
    [J]. BREAST JOURNAL, 2011, 17 (01): : 109 - 111
12345